This is a summary of the European public assessment report (EPAR) for Imlygic. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Imlygic. For practical information about using Imlygic, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
Therapeutic Area (MeSH)
ATC Code
L01XX51
ATC Item
N/A
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| talimogene laherparepvec | N/A | talimogene laherparepvec |
EMA Name
Imlygic
Medicine Name
Imlygic
Aliases
N/ANo risk management plan link.
